Beijing SL Pharmaceutical (002038.SZ) joint venture company Xuanzhu Biosciences is expected to be listed on the Hong Kong Stock Exchange on October 15th.
Shuangliu Pharmaceutical Co., Ltd. (002038.SZ) announced that its equity investment company Xuanzhu Biological (02575) is expected to...
Beijing SL Pharmaceutical (002038.SZ) announced that its affiliated company, Xuanzhu Biotech (02575), is expected to officially list on the Hong Kong Stock Exchange on October 15, 2025. According to the global prospectus disclosed by Xuanzhu Biotech, the company will issue 67.3335 million shares at a price of HK$11.60 per share. Beijing SL Pharmaceutical holds a total of 1.7808 million shares, which is expected to account for 0.34% of the total number of shares issued after the listing. The lock-up period for Xuanzhu Jinyu Bio-Technology held by the company is 12 months after Xuanzhu Biotech's listing.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
